Pharmaids Pharmaceuticals share news, announcements and annual reports
BSE: 524572Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹28.42.
30 Oct: open ₹28.00, high ₹28.89, low ₹27.50
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹98 Cr2,774th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.05
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −8.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹6.70 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −21.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −15.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.44
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,285
Pharmaids Pharmaceuticals share news and announcements
617 announcements, routine notices left out, newest first. Page 3 of 13.
Dec 2024
Nov 2024
13 Nov · Announcement Under Regulation 30 - Contact Details Of KMP For Determining Materiality Of Event/ Information And Making Disclosure.
7 Nov · Board meeting
Meeting on 13 Nov 2024: quarterly results4 Nov · Legal
Exchange has sought clarification from Pharmaids Pharmaceuticals Ltd on November 4, 2024, with reference to Movement in Price. The reply is awaited.
Oct 2024
Sep 2024
26 Sep · Announcement under Regulation 30 (LODR)-Demise
Aug 2024
20 Aug · Board meeting
Meeting on 28 Aug 2024: annual general meeting13 Aug · Results
13 Aug · Board meeting
8 Aug · Announcement Under Regulation 31A(8)(D) - Intimation Of Receipt Of Approval By The Stock Exchange For Application For Reclassification Of Person Forming Part Of The Promoter / Promoter Group From 'Promoter & Promoter Group Category To Public Category' Shareholder Of The Company Pursuant To Regulation 31A Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI LODR Regulations'
Jul 2024
29 Jul · Intimation Of Receipt Of Approval By The Stock Exchange For Application For Reclassification Of Person Forming Part Of The Promoter / Promoter Group From 'Promoter & Promoter Group Category To Public Category' Shareholder Of The Company Pursuant To Regulation 31A Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI LODR Regulations'
Jun 2024
3 Jun · Meeting
May 2024
28 May · Business
21 May · Board meeting
Meeting on 28 May 2024: audited results